Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 13/20 | 0.74 |
| ▸ | MAOB | P27338 | 2/20 | 0.74 |
| ▸ | CALML3 | P27482 | 5/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791726 | 0.90 | MAOA (0.82) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL24142408 | 0.90 | MAOA (0.83) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL25759766 | 0.90 | MAOA (0.83) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL24143136 | 0.90 | MAOA (0.71) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL1383497 | 0.87 | MAOA (0.84) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL24142623 | 0.87 | MAOA (0.74) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL3791720 | 0.87 | MAOA (0.78) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL22238896 | 0.87 | MAOA (0.81) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL17447335 | 0.86 | MAOA (0.83) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL12997800 | 0.86 | MAOA (0.89) | MAOAMAOBCALML3CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348447-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230219941-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219941-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230126415-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230126415-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-11566023-B2 | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof | AKAGERA MEDICINES, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210403463-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | AKAGERA MEDICINES, INC. | 2021-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403463-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | OXA1L, THPO, TBCD | MAOA 1751/4885MAOB 1216/4885CALML3 2409/4885 |
| US-20230126415-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | OXA1L, THPO, TBCD | MAOA 1751/4885MAOB 1216/4885CALML3 2409/4885 |
| US-20230219941-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF | OXA1L, THPO, TBCD | MAOA 1955/4885MAOB 1447/4885CALML3 2394/4885 |
| US-11566023-B2 | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof | OXA1L, THPO, TBCD | MAOA 1751/4885MAOB 1216/4885CALML3 2409/4885 |
| US-20230348447-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | OXA1L, THPO, TBCD | MAOA 1751/4885MAOB 1216/4885CALML3 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.